Spyre Therapeutics, Inc.
SYRE
$14.13
-$0.80-5.36%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 0.00 |
| Cost of Revenue | 162.79M | -- | -- | 34.93M | 84.05M |
| Gross Profit | -162.79M | -- | -- | -34.93M | -84.05M |
| SG&A Expenses | 10.77M | 10.65M | 11.51M | 12.85M | 14.07M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 61.25M | 55.39M | 44.15M | 47.77M | 47.75M |
| Operating Income | -61.25M | -55.39M | -44.15M | -47.77M | -47.75M |
| Income Before Tax | -56.30M | -69.01M | -38.84M | -43.83M | -63.18M |
| Income Tax Expenses | 1.00K | 18.00K | -- | 32.00K | 0.00 |
| Earnings from Continuing Operations | -56.30M | -69.03M | -38.84M | -43.86M | -63.18M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.30M | -69.03M | -38.84M | -43.86M | -63.18M |
| EBIT | -61.25M | -55.39M | -44.15M | -47.77M | -47.75M |
| EBITDA | -61.07M | -55.21M | -43.96M | -47.59M | -47.75M |
| EPS Basic | 0.04 | -1.36 | -0.86 | -1.20 | 11.58 |
| Normalized Basic EPS | -0.64 | -0.85 | -0.54 | -0.75 | -2.60 |
| EPS Diluted | 0.04 | -1.36 | -0.86 | -1.20 | 11.58 |
| Normalized Diluted EPS | -0.64 | -0.85 | -0.54 | -0.75 | -2.60 |
| Average Basic Shares Outstanding | 55.26M | 50.89M | 45.32M | 36.51M | 15.61M |
| Average Diluted Shares Outstanding | 55.26M | 50.89M | 45.32M | 36.51M | 15.61M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |